Baird analyst Eric Coldwell raised the firm’s price target on Medpace to $226 from $217 and keeps a Neutral rating on the shares. The analyst noted they blew out 3Q expectations and already issued impressive 2023 guidance. he said the outlook factored several conservative inputs, though management remains cautiously optimistic that business environment and internal drivers remain in gear.
Published first on TheFly
